AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nektar Therapeutics announced it will participate in the Jefferies Global Healthcare Conference in London on November 20, 2025, with a fireside chat webcast available at 11:00 a.m. GMT/3:00 a.m. PST. The company's lead product candidate, rezpegaldesleukin, is a regulatory T cell stimulator being evaluated in Phase 2b clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet